Diverticulitis Disease Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The diverticulitis disease market size has grown rapidly in recent years. It will grow from $1.85 billion in 2024 to $2.04 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to aging population, dietary habits, obesity, advancements in medical imaging.

The diverticulitis disease market size is expected to see strong growth in the next few years. It will grow to $2.92 billion in 2029 at a compound annual growth rate (CAGR) of 9.4%. The growth in the forecast period can be attributed to colonoscopy and endoscopy, increased awareness, minimally invasive procedures, personalized medicine. Major trends in the forecast period include preventive measures, enhanced diagnostic tools, collaborative care models, healthcare policy changes.

The increasing prevalence of smoking addiction is anticipated to drive the growth of the diverticulitis disease market in the coming years. This rise in smoking addiction is fueled by factors such as aggressive marketing, social acceptance, stress, and the addictive nature of nicotine. The availability of e-cigarettes and vape devices, along with social influences and peer pressure, particularly among youth, further contributes to the rising smoking rates. Smoking is linked to an increased risk of developing diverticular disease as it impairs blood flow to the colon and can lead to severe complications, thereby elevating the demand for diagnostic and therapeutic options. For example, in July 2022, Statistics Canada, a Canadian government agency, reported a 5.8% increase in cigarette production compared to June 2021, with total cigarette sales rising by 1.3% from May 2022 to reach 1.4 billion in June 2022. Consequently, the increasing prevalence of smoking addiction is driving the growth of the diverticulitis disease market.

The rising prevalence of diabetes is also expected to propel the growth of the diverticulitis disease market. This trend is mainly driven by factors such as diets high in processed foods, sedentary lifestyles, increasing obesity rates, genetic predispositions, and an aging population. Diabetes increases the risk of complications like weakened blood vessels, making the colon more vulnerable to infections and inflammation, thus creating greater demand for treatments and therapies. For instance, in June 2024, NHS England, the UK’s publicly funded healthcare system, reported that the number of individuals identified with pre-diabetes rose to 3,615,330 in 2023, marking an 18% increase from 3,065,825 in 2022. Among those under 40, cases surged nearly 25%, from 173,166 in 2022 to 216,440 in 2023. Therefore, the growing prevalence of diabetes is contributing to the expansion of the diverticulitis disease market.

Increasing healthcare expenditures are also expected to drive the growth of the diverticulitis disease market. Health expenditures encompass all costs associated with providing health services, family planning activities, nutrition programs, and emergency health assistance. A rise in healthcare spending significantly supports the development of more effective therapies and medical technologies for treating diverticulitis disease. For instance, in May 2023, the UK’s Office for National Statistics reported that healthcare spending in the UK reached approximately $362.08 billion (£292 billion), reflecting a 5.6% nominal increase. Additionally, long-term health and social care expenditure grew by 2.8% in real terms in 2022. As a result, the increase in healthcare expenditure is fostering growth in the diverticulitis disease market.

Major companies operating in the diverticulitis disease market are developing innovative drugs and getting them approved to sustain their position in the market. Drug development can lead to the development of more effective treatments for diverticulitis, reducing the risk of complications and improving patient outcomes. For instance, in April 2023, the United States Food and Drug Administration, a US-based federal organization, approved Seres' microbiota drug for recurrent gut infections. This drug is designed to treat recurring gut infections and prevent the recurrence of Clostridioides difficile (C. diff.) infections in adults aged 18 and over. The approval of Vowst was based on a clinical trial that enrolled 346 patients with recurrent CDI. The trial found that patients who received Vowst were significantly less likely to experience a recurrence of the infection than those who received a placebo. The drug is taken orally and is based on microbiota containing Firmicutes spores, which are known to contribute to a healthy microbiome that can resist C. diff. colonization.

Major companies operating in the diverticulitis disease market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Company, Cipla Limited, Hikma Pharmaceuticals PLC, Endo Pharmaceuticals, Aspen Pharmacare, Zydus Lifesciences, Lupin Limited, Glenmark Pharmaceuticals, Alkem Laboratories, Torrent Pharmaceuticals Ltd.

North America was the largest region in the diverticulitis disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in diverticulitis disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the diverticulitis disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The diverticulitis disease market consists of revenues earned by entities by providing diagnostic services, pain management, nutritional therapy and follow-up services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diverticulitis disease market also includes sales of antibiotics, dietary supplements, high-fiber foods and pain medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Diverticulitis disease is a medical condition marked by inflammation or infection of small pouches that develop in the walls of the colon or large intestine. Symptoms may encompass lower abdominal pain, constipation, diarrhea, and rectal bleeding.

The disease is categorized into two main types sush as uncomplicated and complicated. Uncomplicated diverticulitis refers to the inflammation or infection of these small pouches, known as diverticula, within the colon walls. Various diagnostic methods such as computed tomography (CT) scans, ultrasounds, urine tests, and blood tests are employed. Treatment options encompass medications, surgery, supportive care, penicillin antibiotics, other antibiotics, dietary supplements, and intravenous (IV) fluids. These treatments are utilized by diverse end-users, including specialty centers, hospitals, and research centers.

The diverticulitis disease market research report is one of a series of new reports that provides diverticulitis disease market statistics, including diverticulitis disease industry global market size, regional shares, competitors with a diverticulitis disease market share, detailed diverticulitis disease market segments, market trends and opportunities and any further data you may need to thrive in the diverticulitis disease industry. This diverticulitis disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.